Trial Profile
A Multi-center, Non-randomized, Non Blinded, Non-controlled Study to Investigate the Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease Associated Pulmonary Hypertension
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Riociguat (Primary)
- Indications Interstitial lung diseases; Pulmonary hypertension
- Focus Adverse reactions
- Sponsors Bayer; Bayer HealthCare
- 20 Nov 2023 Planned End Date changed from 1 Oct 2024 to 1 Oct 2025.
- 20 Nov 2023 Planned primary completion date changed from 1 Oct 2024 to 1 Oct 2025.
- 05 Aug 2021 Planned End Date changed from 1 Oct 2021 to 1 Oct 2024.